OR3O

Device Smith+Nephew, Inc.
Total Payments
$448,214
Transactions
252
Doctors
127
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2021 $424,095 222 115
2020 $24,119 30 16

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $310,478 34 69.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $91,803 17 20.5%
Consulting Fee $16,825 13 3.8%
Travel and Lodging $15,495 45 3.5%
Food and Beverage $7,678 141 1.7%
Space rental or facility fees (teaching hospital only) $5,935 2 1.3%

Payments by Type

Research
$310,478
34 transactions
General
$137,736
218 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and revision total hip arthroplasty (THA) procedures Smith+Nephew, Inc. $289,278 0
Early clinical outcomes for the OR3O dual mobility hip system in Primary and Revision Total Hip Arthroplasty - A data capture study Smith+Nephew, Inc. $21,200 0

Top Doctors Receiving Payments for OR3O — Page 6

Doctor Specialty Location Total Records
, M.D Orthopaedic Surgery Virginia Beach, VA $11.97 1
, PA Physician Assistant Orchard Park, NY $9.19 1
, M.D Orthopaedic Surgery Amherst, NY $9.19 1

About OR3O

OR3O is a device associated with $448,214 in payments to 127 healthcare providers, recorded across 252 transactions in the CMS Open Payments database. The primary manufacturer is Smith+Nephew, Inc..

Payment data is available from 2020 to 2021. In 2021, $424,095 was paid across 222 transactions to 115 doctors.

The most common payment nature for OR3O is "Unspecified" ($310,478, 69.3% of total).

OR3O is associated with 2 research studies, including "Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and revision total hip arthroplasty (THA) procedures" ($289,278).